This article is more than 5 years old. Information may no longer be current.
PUBLICATION EXCLUSIVE: MIGS at 4 years: Where are we now and where are we going?
Click Here to Manage Email Alerts
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.
While much of the attention regarding new technology in anterior segment surgery has been surrounding advances in IOLs and femtosecond laser technology, minimally invasive glaucoma surgery (MIGS) is now becoming a topic of interest for the anterior segment surgeon. This month, Carlos Buznego, MD, summarizes the current landscape in the world of MIGS. We hope you enjoy the discussion.
Kenneth A. Beckman, MD, FACS
OSN CEDARS/ASPENS Debates Editor“What do you mean my child needs glaucoma surgery?” the concerned father asked the ophthalmologist. “And the risk of complications and reoperation are that high? Why can’t you just fix the natural drainage system?” It was that last question that triggered California glaucoma specialist Dr. Richard Hill to discuss his novel idea of a trabecular bypass with the parent, a venture capitalist. The two came together to bring the original idea of minimally invasive glaucoma surgery to fruition. It took nearly a decade and the work of hundreds of engineers, medical scientists, surgeons and patients, but the iStent (Glaukos) finally reached the hands of eye surgeons in the summer of 2012 when it received FDA approval.
Four years have passed since the introduction of the first MIGS implant — where are we now and where are we going?
• Click here to read the full publication exclusive, Cedars/Aspens Debates, published in Ocular Surgery News U.S. Edition, October 25, 2016.